Cancer treatment startup AUM Biosciences raises US$27m in Series A funding
BIOTECH startup AUM Biosciences has raised US$27 million in a Series A funding round to advance its development of therapies for cancer, especially those with a clear genetic marker.
Investors in the round include Singapore-based Everlife, a distribution platform for clinical diagnostics and life sciences in South Asia, and health science venture capital firm SPRIM Global Investments.
AUM will use the funds for the clinical development of its portfolio with immediate initiation of two Phase II programmes for MNK and TRK inhibitors.
Earlier this year, AUM entered into a strategic collaboration agreement with pharmaceutical companies Handok and CMG Pharmaceutical. It also announced a partnership with Newsoara Biopharma to co-develop and co-discover next-generation cancer therapeutics.
Arjun Oberoi, executive chairman of Everlife, said: "Everlife has a strong inclination in expanding its presence in the cancer diagnostic arena. This collaboration will help position us more strongly in the overall oncology ecosystem and grants us immediate access to AUM's network of research laboratories and those of its partners in South-east Asia."
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Startups
Vietnam education startup Prep bags US$7 million in Series A funding
Cruise operator Viking prices IPO within range to raise US$1.54 billion: source
Ninja Van axes more than 20 employees in tech team in Singapore
Temasek-backed PsiQuantum to build first commercial quantum computer
Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too
GoTo narrows Q1 loss to 420 billion rupiah with TikTok deal, cost cuts